AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Data describe selectivity, efficacy, lack of toxicity of oncolytic adenovirus.
2004 SEP 18 - (NewsRx.com & NewsRx.net) -- Geron Corp. (GERN) announced the publication of research demonstrating selectivity, efficacy, and lack of toxicity of an oncolytic virus containing the human telomerase promoter.
The work was published in the August 2004 issue of Cancer Gene Therapy by scientists from Genetic Therapy, Inc., (an affiliate of Novartis, AG) and Cell Genesys, Inc.
Oncolytic viruses are designed to treat cancer by employing the natural properties of lytic viruses - they invade cells, replicate inside the cell until it is destroyed, and then spread to adjacent cells where the process is repeated. In one class of oncolytic virus, the virus is engineered using a promoter that is preferentially active in tumor cells to control expression of a gene necessary for viral replication. The result is that the virus replicates in - and kills - cancer cells without damaging most other cells.
The new publication describes an oncolytic adenovirus (CG 4030) that contains 2 tumor-selective promoters, each driving a gene in the virus that is required for viral replication: the telomerase promoter (active in over 90% of all human cancers) driving the viral E4 gene, and the E2F-1 promoter (active in tumors that have a defective Rb pathway, approximately 85% of all human cancers) driving the E1A gene. In vitro assays showed the virus killed multiple human cancer cell lines while having little effect on normal cells, including cultures of primary liver cells. This virus was significantly less toxic in normal liver cells than an earlier version which did not contain the telomerase promoter.
The researchers administered the virus intravenously to mice and found it to be well-tolerated, as well as less toxic than the ...
- Geron Receives U.S. Patent for Human Telomerase Promoter Triggering Milestone...
- Press release article from: Business Wire August 26, 2003 700+ words
...Geron had non-exclusively licensed the hTERT promoter to Genetic Therapy, Inc. ("GTI"), a subsidiary of Novartis AG, for...Development. "Our scientists have a strong interest in the telomerase promoter and we are eager to continue working with it in our oncolytic...
- Geron's Telomerase Promoter to be Highlighted At the Annual Meeting of the...
- Press release article from: Business Wire May 30, 2002 700+ words
...Abstracts Highlight the Universality of Telomerase Promoter-Based Therapies and Telomerase...effectiveness and universality of the telomerase promoter technology, telomerase and associated...regression after treatment with the telomerase promoter-controlled virus. In 43 percent...
- Noninvasive imaging may show telomerase promoter activity in humans.
- Newspaper article from: Obesity, Fitness & Wellness Week September 25, 2004 700+ words
...Noninvasive imaging may show telomerase promoter activity in humans. "We have assessed...measure the pattern of expression of telomerase promoter fragments in vivo," scientists...gene could be applied to measure telomerase promoter activity in humans," researchers...
- Geron Corporation Announces Study Results Demonstrating the Utility of...
- Press release article from: Business Wire April 5, 2001 700+ words
...demonstrates the utility of the human telomerase promoter to drive the preferential expression...April 4 issue of Gene Therapy, the telomerase promoter, which drives the restricted expression...therapeutic gene under control of the telomerase promoter killed the cancer cells ...
- Telomerase promoter gene therapy jumpstarts lung cancer cell apoptosis.
- Newspaper article from: Cancer Gene Therapy Week September 20, 2004 700+ words
...NewsRx.com & NewsRx.net) -- Telomerase promoter gene therapy jumpstarts lung cancer cell apoptosis...mediated HSV-TK gene therapy using the human telomerase promoter induced apoptosis of small cell lung cancer...
- Geron wins patent for human telomerase promoter, triggers payment.
- Newspaper article from: Gene Therapy Weekly September 25, 2003 700+ words
...telomerase reverse transcriptase gene (the "hTERT promoter"). Geron had nonexclusively licensed the hTERT promoter to Genetic Therapy, Inc., (GTI), a subsidiary of Novartis, AG, for use in the development of viruses that are designed to target cancer...
- Study Demonstrates Utility of Telomerase Promoter.(in cancer cells)
- Newspaper article from: Biotech Week April 18, 2001 700+ words
...net) -- Geron Corp. (GERN) announced the publication of a study that demonstrates the utility of the human telomerase promoter to drive the preferential expression of therapeutic genes in cancer cells. The research, described in the April...
- Study Demonstrates Utility of Telomerase Promoter.
- Newspaper article from: Gene Therapy Weekly April 19, 2001 700+ words
...net) -- Geron Corp. (GERN) announced the publication of a study that demonstrates the utility of the human telomerase promoter to drive the preferential expression of therapeutic genes in cancer cells. The research, described in the April...